Meta-Analysis of Candidate Surrogate End Points in Advanced Prostate Cancer-Reference-Cited by-同舟云学术

Meta-Analysis of Candidate Surrogate End Points in Advanced Prostate Cancer

Published:2023-03-28 Issue:4 Volume:2 Page:
ISSN:2766-5526
Container-title:NEJM Evidence
language:en
Short-container-title:NEJM Evidence

Author:

Gharzai Laila A.¹,Jiang Ralph²,Jaworski Elizabeth M.³,Morales Rivera Krystal³,Dess Robert T.³,Jackson William C.³,Hartman Holly E.⁴,Mehra Rohit⁵,Kishan Amar U.⁶,Solanki Abhishek A.⁷,Schaeffer Edward M.⁸,Feng Felix Y.⁹,Zaorsky Nicholas G.¹⁰,Berlin Alejandro¹¹,Ponsky Lee¹²,Shoag Jonathan¹²,Sun Yilun⁴,Schipper Matthew J.²³,Garcia Jorge¹³,Spratt Daniel E.¹⁰

Affiliation:

1. Department of Radiation Oncology, Northwestern University, Chicago

2. Department of Biostatistics, University of Michigan, Ann Arbor

3. Department of Radiation Oncology, University of Michigan, Ann Arbor

4. Department of Population and Quantitative Health Sciences, Case Western Reserve, Cleveland, OH

5. Department of Pathology, University of Michigan, Ann Arbor

6. Department of Radiation Oncology, University of California, Los Angeles, Los Angeles

7. Department of Radiation Oncology, Stritch School of Medicine, Cardinal Bernardin Cancer Center, Loyola University Chicago, Maywood, IL

8. Department of Urology, Northwestern University, Chicago

9. Department of Radiation Oncology, University of California, San Francisco, San Francisco

10. Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve, Cleveland, OH

11. Department of Radiation Oncology, University of Toronto; Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, ON

12. Department of Urology, University Hospitals Cleveland Medical Center, Case Western Reserve, Cleveland, OH

13. Department of Medicine, University Hospitals Seidman Cancer Center, Case Western Reserve, Cleveland, OH

Publisher

Massachusetts Medical Society

Reference24 articles.

1. The promise and peril of surrogate end points in cancer research

2. Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer

3. Event-Free Survival, a Prostate-Specific Antigen–Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation

4. Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis

5. The validation of surrogate endpoints in meta-analyses of randomized experiments

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Is It Premature to Accept Radiographic Progression-Free Survival as a Surrogate End Point in Metastatic Hormone-Sensitive Prostate Cancer?;Journal of Clinical Oncology;2024-08-20

2. Design issues with lutetium-177 PSMA-617 registration studies that bias the outcome of the experimental arm reflect an increasing misalignment of contemporary oncology trials with true patient benefit;BJC Reports;2024-06-24

3. Delaying Prostate-Specific Antigen Progression in Biochemically Recurrent Prostate Cancer: Is It Clinically Meaningful?;Journal of Clinical Oncology;2024-04-01

4. The State of Intermediate Clinical Endpoints as Surrogates for Overall Survival in Prostate Cancer in 2024;European Urology Oncology;2024-04

5. Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer;Journal of Clinical Oncology;2024-03-20